KPTI logo

Karyopharm Therapeutics (KPTI) Company Overview

Profile

Full Name:

Karyopharm Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

November 6, 2013

Indexes:

Not included

Description:

Karyopharm Therapeutics is a biopharmaceutical company focused on developing innovative treatments for cancer and other serious diseases. They specialize in creating drugs that target the nuclear transport system, aiming to improve patient outcomes and provide new options for difficult-to-treat conditions.

Key Details

Price

$0.64

Annual Revenue

$146.03 M(-7.03% YoY)

Annual EPS

-$1.25(+38.12% YoY)

Annual ROE

105.06%

Beta

0.52

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 5, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 15, 25 HC Wainwright & Co.
Buy
Nov 6, 24 Piper Sandler
Overweight
Nov 6, 24 HC Wainwright & Co.
Buy
Nov 1, 24 HC Wainwright & Co.
Buy
Aug 7, 24 RBC Capital
Outperform
Aug 7, 24 HC Wainwright & Co.
Buy
Aug 7, 24 Baird
Outperform
Jun 28, 24 HC Wainwright & Co.
Buy
Jun 3, 24 HC Wainwright & Co.
Buy
May 9, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
KPTI
prnewswire.comJanuary 13, 2025

– Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 –  – Recently Announced Key Leadership Changes, including the Appointment of Lori Macomber as Chief Financial Officer and Brendan Strong as SVP of Investor Relations and Corporate Communications –  – Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively – NEWTON, Mass. , Jan. 13, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2024 achievements and 2025 objectives.

Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?
Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?
Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?
KPTI
Insider MonkeyJanuary 7, 2025

We have put together a list of the 12 Best Penny Stocks to Invest in Based on Media Recommendations. In this article, we will examine how Karyopharm Therapeutics Inc. (NASDAQ:KPTI) compares to other top penny stocks suggested by the media. Additionally, we will discuss the outlook for small-cap stocks in 2025.

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
KPTI
prnewswire.comDecember 9, 2024

NEWTON, Mass. , Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications.

Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
KPTI
prnewswire.comDecember 3, 2024

NEWTON, Mass. , Dec. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial.

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
KPTI
zacks.comNovember 5, 2024

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
prnewswire.comNovember 5, 2024

– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass. , Nov. 5, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
KPTI
prnewswire.comOctober 30, 2024

Company to host a conference call tomorrow at 8:00 a.m. ET NEWTON, Mass.

Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
KPTI
zacks.comSeptember 5, 2024

Karyopharm Therapeutics (KPTI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
prnewswire.comAugust 6, 2024

– Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US with Continued Regulatory and Reimbursement Approvals – – Updated Clinical Results at ASCO Annual Meeting Showed Median Progression-Free Survival (PFS) of 28.4 Months in the TP53 Wild-Type Exploratory Subgroup and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type Exploratory Subgroup from Phase 3 SIENDO Study of Selinexor Maintenance Treatment in Advanced/Recurrent Endometrial Cancer – – Pre-Clinical Data Presented at the June 2024 European Hematology Association Meeting Support Selinexor's Mechanism of Action Targeting Multiple Oncogenic Pathways beyond JAK/STAT and Builds on the Compelling Clinical Data in Myelofibrosis – – Completed Significant Refinancing Transactions and Amended Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts and Potential Approvals from the Company's Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – –  Raises the Lower End of Full-Year 2024 Total Revenue Guidance to $145.0 Million to $160.0 Million and U.S. XPOVIO Net Product Revenue Guidance to $105.0 Million to $120.0 Million; Lowers Full Year 2024 R&D and SG&A Expense Guidance to $250.0 Million to $265.0 Million – NEWTON, Mass. , Aug. 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
KPTI
prnewswire.comJuly 31, 2024

-- Conference Call Scheduled for Tuesday, August 6, 2024, at 8:00 a.m. ET -- NEWTON, Mass.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Karyopharm Therapeutics?
  • Does Karyopharm Therapeutics pay dividends?
  • What sector is Karyopharm Therapeutics in?
  • What industry is Karyopharm Therapeutics in?
  • What country is Karyopharm Therapeutics based in?
  • When did Karyopharm Therapeutics go public?
  • Is Karyopharm Therapeutics in the S&P 500?
  • Is Karyopharm Therapeutics in the NASDAQ 100?
  • Is Karyopharm Therapeutics in the Dow Jones?
  • When was Karyopharm Therapeutics's last earnings report?
  • When does Karyopharm Therapeutics report earnings?
  • Should I buy Karyopharm Therapeutics stock now?

What is the ticker symbol for Karyopharm Therapeutics?

The ticker symbol for Karyopharm Therapeutics is NASDAQ:KPTI

Does Karyopharm Therapeutics pay dividends?

No, Karyopharm Therapeutics does not pay dividends

What sector is Karyopharm Therapeutics in?

Karyopharm Therapeutics is in the Healthcare sector

What industry is Karyopharm Therapeutics in?

Karyopharm Therapeutics is in the Biotechnology industry

What country is Karyopharm Therapeutics based in?

Karyopharm Therapeutics is headquartered in United States

When did Karyopharm Therapeutics go public?

Karyopharm Therapeutics's initial public offering (IPO) was on November 6, 2013

Is Karyopharm Therapeutics in the S&P 500?

No, Karyopharm Therapeutics is not included in the S&P 500 index

Is Karyopharm Therapeutics in the NASDAQ 100?

No, Karyopharm Therapeutics is not included in the NASDAQ 100 index

Is Karyopharm Therapeutics in the Dow Jones?

No, Karyopharm Therapeutics is not included in the Dow Jones index

When was Karyopharm Therapeutics's last earnings report?

Karyopharm Therapeutics's most recent earnings report was on Nov 5, 2024

When does Karyopharm Therapeutics report earnings?

The next expected earnings date for Karyopharm Therapeutics is Feb 28, 2025

Should I buy Karyopharm Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions